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Objective. This study tests whether sialic acid is a mediator of the lung injury following lower extremity
ischemia/reperfusion (I/R).
Design. Prospective randomised study.
Materials and Methods. Thirty-one Sprague–Dawley rats were randomised into four groups: group 1, aorta was exposed
but not clamped; group 2, aorta clamped for 3 h, followed by 1 h of reperfusion; group 3, 50 mg/kg pentoxifylline
administrated before the aorta was clamped; and group 4, 1 mg/kg dexametasone administrated before the aorta was clamped.
Serial arterial blood samples for blood gas, tumor necrosis factor-a (TNF-a), and total SA (TSA) assay were obtained. The
lungs were removed and histologically examined for evidence of injury.
Results. Groups 2, 3, and 4 had significantly higher peak serum TSA concentrations compared with groups 1 (group 1 vs. 2,
p ¼ 0.001; group 1 vs. 3, p ¼ 0.002; group 1 vs. 4, p ¼ 0.001). Group 3 had lower peak serum TSA concentration. Groups 2
and 4 had significantly higher peak serum TNF-a concentrations (p ¼ 0.0001) compared with groups 1 and 3. Group 3 had
lower peak serum TNF-a concentration. Lower TSA and TNF-a levels are associated with lesser degrees of lung injury.
Conclusions. TSA and TNF appear during events that lead to lung injury following lower extremity I/R.
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Introduction
Acute ischemia and reperfusion of an extremity starts
an inflammatory cascade, which eventually causes
injury and damage of the extremity, as well as some
degree of insult to distant target organs as a result of
systemic response. Severe and sometimes fatal pul-
monary complications secondary to this inflammatory
process have been well described before.
Sialic acid (SA) is a member of an acetylated family
of neurominic acid that is widely scattered in
mammalian organisms.1 SA is a fragment of some
glycoproteins and glycopeptides found in the struc-
ture of hormones and enzymes.1,2 A close relationship
has been described between SA and ischemic con-
ditions in recent years.3,4 Also, SA levels correlates
with the acute phase reactants that appear in acute
inflammatory reaction.5,6 Tumor necrosis factor-a
(TNF-a) causes pulmonary injury after hindlimb
ischemia/reperfusion (I/R) model in rats.7 – 9
Although the mechanisms have not been elucidated
completely, recent works indicated that TNF-a is an
essential component of the cascade of events that lead
to I/R-induced lung injury.9,10
The role of sialic acid in ischemia is not clear. The
relation with systemic inflammatory response is clear
and evident in previous works. Here in this presented
study, we wanted to evaluate the correlation between
serum TSA levels and lower limb ischemia. Lower
limb ischemia and reperfusion is known to cause lung
injury which is actually attributed to locally produced
cytokines such as TNF-a. In our study design, we
aimed to look for the changes in serum TSA levels,
where the systemic inflammation is attenuated with
drugs known to attenuate the systemic inflammatory
response. This would enable us to decide whether TSA
is a marker or a mediator in systemic inflammatory
cascades that eventually result in distant organ
damage, mainly to the lung. For this, we have used
pentoxifylline and dexamethasone on this assump-
tion. Since the mediator role of TNF-a in lung injury is
known, this substance, with histopathological exami-
nation of the lungs were investigated for their
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correlative connection with TSA, if it was also a
mediator.
Materials and Methods
An experimental animal study was conducted.
Animal care complied with the ‘Principles of Labora-
tory Animal Care’ as formulated by the National
Society for Medical Research and the Guide for the
Care and Use of Laboratory Animals (NIH publication
No. 86-23, revised 1985). All studies were approved by
the Animal Care and Use Committee of Cumhuriyet
State University Medical Faculty.
Model
The study conducted by Tassiopoulos et al. was
referred to for the planning of the experiments.11 In
short, the study protocol includes the cross clamping
of the infrarenal aorta for 3 h followed by a 1 h
reperfusion period, by removal of the cross-clamp,
which forms a well characterized acute limb ischemia
and reperfusion (I/R) model.
Experimental protocol
Thirty-one adult male Sprague–Dawley rats, weigh-
ing 380–460 g were fasted overnight. Intramuscular
injections of ketamine (75 mg/kg) together with
xylazine (5 mg/kg) were administered for sedation
and anaesthesia. The animals were anaesthetized
throughout the entire procedure with injections of
one-fourth of the initial dose given every 20–30 min.
A carotid arterial catheter was inserted for blood
sample analysis, and a jugular venous line was
established for intravenous fluid infusion through
the same neck incision. The animals were given
heparin of 1000 units/kg. The infrarenal aorta was
exposed through a midline abdominal incision. Rats
were randomized into four study groups:
. In group 1 (control), the aorta was exposed but not
cross-clamped, and the animal was observed for
240 min ðn ¼ 7Þ:
. In group 2, aorta was cross-clamped just above the
bifurcation with special vascular clips for 3 h,
followed by 60 min of reperfusion with the removal
of the vascular clip ðn ¼ 8Þ:
. In group 3, animals were pretreated with 50 mg/kg
pentoxifylline intravenously, before aortic cross
clamping ðn ¼ 9Þ:
. In group 4, animals were pretreated with 1 mg/kg
dexametasone intravenously, before aortic cross
clamping ðn ¼ 7Þ:
Animals in groups 3 and 4 were subjected to the
same I/R time as the animal in group 2. Reperfusion
was achieved with the removal of the vascular clip.
Arterial blood samples were obtained for total SA
(TSA), TNF-a, and blood gas analysis. All the data
were measured at baseline (prior to aortic clamping),
after 90 and 180 min of ischemia, and 30 min after
reperfusion in the study groups. In control group
(group 1) baseline samples were taken when the aorta
was exposed and at 90, 180 and 210 min after this. All
the blood samples (0.5 ml) taken for studies were
replaced with equal volumes of isotonic fluids to
prevent acute volume depletion of the animals.
Sialic acid and TNF-a analysis
TSA assays were centrifuged immediately at 4000 rpm
and serum was collected. These were stored at 220 8C
until assayed. The serum TNF specimens collected
after centrifugation were stored at 270 8C until they
were analysed. An enzymatic assay was used for the
assessment of serum TSA (Boehringer Mannheim).
The results were analyzed spectrophotometrically and
expressed as mg/dL. All TSA determinations were
performed at the same time by an independent
investigator who was blind to the study. The
enzyme-linked immunosorbent assay (ELISA) was
performed using the CytoScreen Rat TNF-a. Kit
(BioSource, Camarillo, CA). The Cytoscreen Rat
TNF-a Kit is a solidphase sandwich ELISA. An
antibody specific for TNF-a was coated onto the
wells of the microtitre strips provided. Samples
(including standards of known TNF-a content), con-
trol specimens and unknowns were pipetted into these
wells. This was followed by the addition of a
biotinylated second antibody. During the first incu-
bation, the TNF-a antigen bound simultaneously to
the immobilized antibody on one site and to the
solution phase biotinylated antibody on a second site.
After removal of the excess second antibody, the
enzyme streptavidin-peroxidase is added. This bound
to the biotinylated antibody to complete the four-
member sandwich. After a second incubation and
washing to remove all unbonded enzymes, a substrate
solution was added, which was acted upon by the
bound enzyme to produce colour. The intensity of this
coloured product is directly proportional to the
concentration of TNF-a present in the original speci-
men. The plates are read spectrophotometrically in a
microplate reader at 450 nm and expressed as pg/ml.
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The intra- and inter-assay coefficients of variation for
the ELISA were 2.7% and 4.3%, respectively.
The animals were sacrificed by intravenous
injection of pentobarbital sodium at the end of the
experiment. The lungs were then removed and
immersion-fixed in formalin. Fixed specimens were
paraffin-embedded, sectioned in 4 mm pieces, and
stained with routine hematoxylin-eosin stain. The
same pathologists who were blind to the study
examined the specimens. At least two different
sections from each specimen were examined to
determine the degree of injury accurately. Lung injury
was recorded according to a semi quantitative score
based on congestion, interstitial edema, PMN infiltra-
tion, and airspace hemorrhage. The scoring included:
0, no changes; 1, focal, mild, subtle changes; 2, multi
focal mild and prominent changes; 3, extensive
prominent changes. Although, this scoring system is
a subjective way of evaluation, two different and
blinded pathologists performed the examination and
scored on every specimen to overcome a possible bias.
Statistical analysis
All the measured values are expressed as mean ^
standard deviation. In univariate analysis, Students
t-test was used where appropriate (parametric
continuous data) and p-values lower than 0.05 were
accepted as significant. For the data where parametric
criteria was not met, Mann–Whitney U test was
applied. Due to multiple groups (more than two)
one-way ANOVA was applied to determine the
differences between groups. Bonferroni corrections
were made and Post Hoc tests (Tukey) were applied to
determine the significantly different data. All these
statistical analyses were carried out with commercially
available software packages.
Results
Total sialic acid changes during the experiment for all
groups are given in Table 1. When compared with
baseline levels, after 90 as well as after 180 min of
ischemia, there was a significant increase in all the
groups except group 1. After 30 min of reperfusion
TSA levels continued to increase in groups 2, 3, and 4,
being significantly higher than the baseline, 90 min as
well as 180 min levels. The differences were significant
between groups 2 and 3, but were not significant
between group 2 and 4 (Table 1).
After 90 min of ischemia tumor necrosis factor-a
(TNF-a), levels had increased in all groups as
compared to the baseline values. The increase was
most pronounced in group 2 and 4 and the differences
were significant when compared with groups 1 and 3
(Table 2). Groups 2, 3 and 4 had significantly higher
levels of TNF-a when compared with group 1
( p ¼ 0:0001). After 180 min of ischemia, TNF-a levels
had decreased significantly in all study groups, but
they were still significantly higher than the baseline
levels. Again, TNF-a levels in group 2 and 4 were
significantly higher than the TNF-a level in group 1
( p ¼ 0:001 for group 1 vs. 2; p ¼ 0:002 for group 1 vs. 4).
After 30 min of reperfusion, TNF-a levels continued to
Table 1. Total sialic acid levels in groups
TSA (mg/dL) Baseline 90 min p-value 180 min p-value 210 min p-value
Group 1 ðn ¼ 7Þ (control) 46 ^ 3 48 ^ 3 0.076 48 ^ 3 0.16 47 ^ 3 0.089
Group 2 ðn ¼ 8Þ (I/R without pretreatment) 47 ^ 2 51 ^ 3 0.002 60 ^ 2 0.0001 72 ^ 4 0.0001
Group 3 ðn ¼ 9Þ (I/R with pentoxyfillin pretreatment) 47 ^ 3 51 ^ 3 0.003 57 ^ 4 0.001 63 ^ 4 0.003
Group 4 ðn ¼ 7Þ (I/R with dexamethasone pretreatment) 47 ^ 3 52 ^ 5 0.002 60 ^ 5 0.0001 71 ^ 5 0.0001
I/R; ischemia/reperfusion. Changes in total sialic acid (TSA) concentration during ischemia/reperfusion. Groups 2, 3, and 4 had significantly
higher peak serum TSA concentrations ðp , 0:05Þ compared with Group 1. Group 3 had lower peak serum TSA concentration compared with
groups 2 and 4 as well. There was no significant difference in TSA levels among these groups (2, 3, and 4) at any point during the course of
ischemic period, except reperfusion. Values are presented as mean ^ standard deviation.
Table 2. Tumor necrosis factor levels in groups
TNF (pg/mL) Baseline 90 min p-value 180 min p-value 210 min p-value
Group 1 ðn ¼ 7Þ (control) 51 ^ 9 561 ^ 68 0.0001 349 ^ 42 0.001 51 ^ 8 0.0001
Group 2 ðn ¼ 8Þ (I/R without pretreatment) 61 ^ 20 917 ^ 109 0.0001 597 ^ 37 0.0001 145 ^ 13 0.0001
Group 3 ðn ¼ 9Þ (I/R with pentoxyfillin pretreatment) 50 ^ 13 767 ^ 79 0.0001 390 ^ 41 0.001 54 ^ 7 0.0001
Group 4 ðn ¼ 7Þ (I/R with dexamethasone pretreatment) 54 ^ 12 930 ^ 147 0.0001 517 ^ 77 0.0001 135 ^ 9 0.0001
I/R; ischemia/reperfusion. Changes in tumor necrozing factor-a (TNF-a) concentration during Ischemia/Reperfusion. Groups 2 and 4 had
significantly higher peak serum TNF-a concentrations ðp , 0:05Þ compared with groups 1 and 3. Group 3 had lower peak serum total sialic
acid concentration compared with group 1. TNF-a levels decreased significantly, in all study groups end of the ischemic period. During
reperfusion, TNF-a levels continued to decrease and almost returned to baseline levels. Values are presented as mean ^ standard deviation.
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decrease and returned to baseline levels in group 1 and
3. The difference in group 2 and group 4 between
TNF-a levels were not different, but still these groups
had higher levels when compared with group 1 and 3
(Table 2).
Throughout the experiments, pH remained
unchanged in groups 1, 3, and 4. In contrast, in
group 2 the pH decreased significantly during the
reperfusion, indicating a degree of systemic metabolic
acidosis (Fig. 1).
Histological evaluation revealed significant differ-
ences in the degree of lung injury between groups
(Fig. 2). Groups 1 and 3 had lesions ranging from 0 to
1þ , with average injury scores of 0.57, 0.88 respect-
ively. Groups 2 and 4 exhibited extensive, prominent
histological changes ranging from 1þ to 3þ and an
average injury score of 2.62 and 2.42 ( p ¼ 0:001 for
group 1 vs. 2; p ¼ 0:002 for group 1 vs. 4; p ¼ 0:003 for
group 3 vs. 2; p ¼ 0:003 for group 3 vs. 4).
Discussion
A correlation of plasma TSA levels and acute phase
reactants in acute inflammations have been
described,5,6 but the relation between ischemia and
TSA is not clear. Ischemia of the lower extremities in a
rat model caused significant increases in serum TSA
levels in our study. As the ischemia continued, serum
TSA rose as well. In our study groups, 90 min TSA
levels were significantly higher compared to baseline
levels and control group and reached higher levels at
180 min. This might be due to induction of systemic
inflammation. Reperfusion of ischemic extremities
also resulted with steady increases in TSA levels.
Even though statistically non-significant, pentoxifyl-
line seems to attenuate the rise of TSA during
ischemia. This was not observed in dexamethasone
pretreated group. TSA levels were slightly lower in
group 3, compared to groups 2 and 4, after 3 h of hind
limb ischemia. During the reperfusion period, a
statistically significant difference was reached in
group 3, compared to group 2 and group 4 (Table 1).
Pentoxifylline is known to decrease the release of
various cytokines, including TNF-a.12 – 14 Since TSA is
a sensitive marker of inflammation, lower levels of
TSA in group 3 can be due to pentoxifylline.
Lower extremity ischemia/reperfusion induces
TNF-a production, but the exact cells responsible
were not identified.7 – 11 In the work by Tassiopoulos
et al., TNF-a levels reach their peak after 1 h and
returned to baseline levels after 3 h.11 Even though the
sampling times were different in this study, we
observed significant increases at 90 min in groups 2,
3, and 4. The increase in control group was consider-
ably lower, and was probably due to a response to
surgical trauma. Major changes achieved in TNF-a
levels with lower torso ischemia did not correlate with
the duration of the ischemia in our study. Levels of
TNF-a decreased significantly at 180 min and in the
reperfusion period in all groups. We believe that
TNF-a is one of the cytokines that is responsible for the
induction of systemic inflammatory response, but a
negative feedback might be responsible (which is still
obscure to us) for the decrease after the acute phase.
The rise of TSA did not correlate with blood TNF-a
Fig. 1. pH changes during ischemia/reperfusion in four groups. Group 2 had significantly lower pH compared with groups
1, 3, and 4 during reperfusion, indicating development of metabolic acidosis, which was worse in group 2. Values are
presented as mean ^ standard deviation. Group 1: control group, Group 2: ischemia/reperfusion without any pretreatment,
Group 3: ischemia/reperfusion with pentoxyfillin pretreatment, Group 4: ischemia/reperfusion with dexamethasone
pretreatment.
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levels during the experimental protocol. Both of these
molecules are probably indicators of the different
events, but not directly responsible from the damage
caused by ischemia or following reperfusion.
Pentoxifylline pretreated group showed lower
increases of TNF-a, compared with group 2 and 4,
but was still higher than group 1 at 90 and 180 min.
Pentoxifylline increases c-AMP, which might be
mechanism that lowers TNF-a levels.12,14 These
actions of pentoxifylline may be due to its inhibitory
effects on systemic inflammatory response. These
effects were not achieved with dexamethasone in
our study. Although contradicting with previous
reports,15 – 17 anti-inflammatory effect of dexametha-
sone was not evident in our study which may be due
to the dose used in our work. It could be stated
that dexamethasone’s anti-inflammatory effects are
evident if given after the inflammation takes place,
instead of pretreatment. Pretreatment with dexa-
methasone did not prevent the lung injury after I/R
without a logical explanation in our study.
TNF-a mediates lung injury by activating poly-
morphonuclear neutrophils and enhancing their
sequestration to lung.18 Blockade of TNF-a release or
activity can reduce neutrophil chemotaxis and seques-
tration, and attenuate the lung injury processes.15 – 17 In
previous reports, administration of pentoxifylline or
dexametasone before ischemia was shown to inhibit
the release of TNF-a and protect the lung against I/R
induced injury.11,17 In the histopathological exami-
nation of lung tissue samples, the pentoxifylline
pretreatment group had lesser injury when compared
to groups 2 and 4. The rats with the highest SA and
TNF-a levels in group 4 had the most severe lung
injury despite the pretreatment with steroids. Lower
TSA and TNF-a levels were associated with lesser
degrees of lung injury, regardless of the pretreatment
drug.
In lower limb ischemia, systemic acidosis is an
expected finding as it occurred in group 2, but it is
not clear why this was not evident in groups 3 and 4
(pretreatment groups). Tissue pH was not measured in
our study. This finding helps us to speculate on the
actions of dexamethasone. In previous works it is
proven to attenuate systemic inflammatory response;
it probably works on local tissue factors during
ischemia. The steady pH in the dexamethasone
group suggests its protective effects on local homeo-
stasis in ischemic tissues, which may not be sufficient
enough to attenuate the systemic inflammatory
response. Many local factors are responsible for the
initiation of systemic inflammatory reaction when a
part of the body is under ischemic threat. These start a
cascade that lead to lung injury. TSA and TNF-a are
involved in these cascades. The results of our study
suggest that TNF-a may be one of the mediators, but
TSA is probably a marker of ongoing reactions or
systemic metabolic changes. We can conclude that, as
Fig. 2. Histological picture of lungs with different degrees of
injury (routine hematoxylin-eosin stain; original
magnification, 75 £ ). A, 1, focal, mild, subtle changes; B, 2,
multifocal mild and prominent changes; C, 3, extensive
prominent changes.
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expected, pentoxifylline pretreatment can attenuate
the inflammatory process.
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